CN102053150B - Human osteosarcoma stem cell related antigen marker and application thereof - Google Patents
Human osteosarcoma stem cell related antigen marker and application thereof Download PDFInfo
- Publication number
- CN102053150B CN102053150B CN 200910197959 CN200910197959A CN102053150B CN 102053150 B CN102053150 B CN 102053150B CN 200910197959 CN200910197959 CN 200910197959 CN 200910197959 A CN200910197959 A CN 200910197959A CN 102053150 B CN102053150 B CN 102053150B
- Authority
- CN
- China
- Prior art keywords
- stem cell
- cell
- ssea
- osteosarcoma
- osteogenic sarcoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000008968 osteosarcoma Diseases 0.000 title claims abstract description 41
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 32
- 239000000427 antigen Substances 0.000 title claims abstract description 9
- 108091007433 antigens Proteins 0.000 title claims abstract description 9
- 102000036639 antigens Human genes 0.000 title claims abstract description 9
- 239000003550 marker Substances 0.000 title abstract description 11
- 210000004027 cell Anatomy 0.000 abstract description 27
- 238000002626 targeted therapy Methods 0.000 abstract description 5
- 239000002458 cell surface marker Substances 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 238000012546 transfer Methods 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 239000000700 radioactive tracer Substances 0.000 abstract description 2
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 11
- 210000001671 embryonic stem cell Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 4
- 102100037241 Endoglin Human genes 0.000 description 3
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 102100024210 CD166 antigen Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a human osteosarcoma stem cell-associated antigen marker SSEA-4 and application thereof in targeted therapy of osteosarcoma. SSEA-4 is a specific osteogenic sarcoma stem cell surface marker that is hardly expressed in every normal adult tissue. The surface marker is easy for antibody marking, does not influence cell activity, is suitable for a function experiment after separation, provides a reliable molecular tracer for further researching the action of stem cells in the origin, generation and development processes of osteosarcoma, and lays a foundation for explaining clinical osteosarcoma drug resistance, transfer and searching for cell and molecular targets for targeted therapy.
Description
Technical field
The present invention relates to the oncobiology field, more particularly, relate to a kind of people's osteogenic sarcoma stem cell related antigen label and application thereof.
Background technology
In recent years, along with to the deepening continuously of tumor stem cell theoretic knowledge, require us that origin and generation, the development of tumour are had more clearly understanding.Especially tumor stem cells such as leukaemia, breast cancer, human glioma and colorectal cancer are separated and identify the report of work, not only confirm and consolidated the tumor stem cell theory, also making becomes focus to the evaluation of other tumor stem cells and the research of inherent molecular mechanism feature.At present, few about the report of osteogenic sarcoma stem cell both at home and abroad, people such as external Gibbs adopted the in vitro culture mode in 2005, from clone, isolate the sarcoma cell ball (sarcosphere) that contains the stem-like cell osteosarcoma cell first, express surface marker (as Stro-1, CD44 and CD105) and the embryonic stem cell characterizing gene (Nanog and Oct-4) of multiple mescenchymal stem cell; There is the SP cell in the human osteosarcoma cell colony of discovery in vitro culture such as Colleen Wu in 2007, but also fails to separate concrete, the specific osteogenic sarcoma stem cell surface label of evaluation.Of paramount importance is that these work all are not based on the research work of people's tumor tissues of former generation, do not carry out inoculation test in strict cell separation and the body.
People such as Gibbs in 2005 isolate sarcoma cell ball and people such as Colleen Wu in 2007 of containing the stem-like cell osteosarcoma cell first and find the SP cell from the sarcoma patient specimens.On the one hand, above-mentioned scholar's work mainly is confined to cell in vitro cultivation level, fails to be created as in vivo phenotype and the function (and this be the goldstandard of tumor stem cell research) of osteosarcoma cell heteroplastic transplantation model to identify the osteogenic sarcoma stem cell; On the other hand, the separation method of SP cell exists hoechst33342 dyestuff toxicity, low, the more high limitation of instrument configuration of cell viability.Thereby separate and identify that specific osteogenic sarcoma stem cell surface label is the technical foundation of carrying out the research of tumor stem cell specific aim.
Existing research and the application of SSEA-4: SSEA-4 is stage specific embryonic antigen4, be belong to the phase specificity embryonal antigen a kind of, glycolipid class antigen as a kind of body early embryo, surface marker as embryonic stem cell and mescenchymal stem cell commonly used, but the evaluation of tumor stem cell and screening never, the present invention for the first time with SSEA-4 as surface marker, as the evaluation of osteogenic sarcoma stem cell.
Summary of the invention
The purpose of this invention is to provide a kind of people's osteogenic sarcoma stem cell related antigen label.
Second purpose of the present invention provides the application of described people's osteogenic sarcoma stem cell related antigen label SSEA-4 in the osteogenic sarcoma targeted therapy.
19 people's osteogenic sarcomas that the present invention utilizes set up early stage are striden species transplantation model and free serum culture technology, in the body and external two aspects, separate and identify the osteogenic sarcoma surface marker SSEA-4 with mescenchymal stem cell and embryonic stem cell double characteristic coexisting with tumor stem cell colony.Surface marker SSEA-4 is easy to antibody labeling, and mark does not influence cell viability, the functional experiment after being fit to separate; Simultaneously SSEA-4 not only points out osteogenic sarcoma may originate from the mescenchymal stem cell stage, for follow-up mechanism research provides concrete minute subobject and model platform.Clinically, the expression degree in a part of patient can be pointed out its grade malignancy, transfer and prognosis situation, is the potential molecular target that can be used as targeted therapy.
Because it is lower that osteogenic sarcoma patient sample of former generation is striden the species transplanting succeed rate, so we have attempted a large amount of clinical samples, obtains 3 animal models at last.In addition, we have detected a plurality of have mescenchymal stem cell and embryonic stem cell surface markers, mark of correlation thing according to expression and article report, the SSEA-4 that selection has mescenchymal stem cell and an embryonic stem cell double characteristic as the osteosarcoma surface marker after, then confirmed, we verify the specificity of label in conjunction with clone and patients clinical sample at last.
SSEA-4 is a specific osteogenic sarcoma stem cell surface label, expresses hardly in each normal adult tissue.This surface marker is easy to antibody labeling, do not influence cell viability, functional experiment after being fit to separate, provide a reliable molecule tracer for further studying stem cell in the effect of origin, generation and the evolution of osteogenic sarcoma, for cell and the molecular target of explaining clinical osteogenic sarcoma resistance, transfer and searching targeted therapy are laid a good foundation.
Description of drawings
Below in conjunction with Figure of description, the present invention is described in more detail.
Fig. 1: the screening of human osteosarcoma cell immunophenotype.Select mescenchymal stem cell and embryonic stem cell surface marker CD105, CD166, CD117, CD90, CD44, STRO-1, SSEA-4, SSEA-3 etc. commonly used.
Fig. 2 A: former generation human osteosarcoma cell expression SSEA-4 and Oct-4; Fig. 2 B: the human osteosarcoma cell of foundation is that 5well expresses SSEA-4 and Oct-4.
Fig. 3: osteogenic sarcoma Pathologic specimen SABC shows that SSEA-4, nanog, oct-4 express.
Fig. 4: the osteogenic sarcoma primary cell forms sphere under external free serum culture condition.
Embodiment
I, we in early-stage Study, adopt former generation sample of just sending out the osteogenic sarcoma patient, be digested to single cell suspension after, utilize free serum culture technology and NOD/SCID mouse successfully to set up the human osteosarcoma cell ball and stride the species transplantation model.By the flow cytometry technology, the human osteosarcoma cell of taking from into the knurl mouse is carried out phenotype analytical, find that these cells often express that SSEA-3, SSEA-4, CD184, CD105, CD166 and CD49d etc. are a plurality of to have mescenchymal stem cell and an embryonic stem cell surface marker.
II, SSEA-4 is carried out more detailed checking: utilize clone, adopt immunofluorescence and SABC to get method, carry out phenotypic evaluation and checking, test expression etc. in former generation sample.
III, by to differentiation more careful between the different surfaces label and comparison, choose the strongest label of sub-fraction specificity, carry out the immunofluorescence antibody labeling, utilize the airflow classification technology that the human osteosarcoma cell of different expressions is sorted out, mode with gradient dilution is implanted into the NOD/SCID mouse respectively, by to becoming the comparative analysis of knurl situation, select the special surface marker the most relevant with osteogenic sarcoma tumorigenesis ability, i.e. SSEA-4.
IV, with the osteogenic sarcoma primary cell that obtains under external free serum culture condition, add cell factors such as FGF, N2B27, can be at external formation human osteosarcoma cell ball (sphere).
Claims (1)
1.SSEA-4 the application in preparation people osteogenic sarcoma stem cell related antigen label.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910197959 CN102053150B (en) | 2009-10-30 | 2009-10-30 | Human osteosarcoma stem cell related antigen marker and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910197959 CN102053150B (en) | 2009-10-30 | 2009-10-30 | Human osteosarcoma stem cell related antigen marker and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102053150A CN102053150A (en) | 2011-05-11 |
| CN102053150B true CN102053150B (en) | 2013-07-17 |
Family
ID=43957688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910197959 Expired - Fee Related CN102053150B (en) | 2009-10-30 | 2009-10-30 | Human osteosarcoma stem cell related antigen marker and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102053150B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110476892A (en) * | 2019-09-09 | 2019-11-22 | 中南大学湘雅二医院 | A kind of construction method of osteosarcoma xenograft mouse model and application |
| CN110402895A (en) * | 2019-09-09 | 2019-11-05 | 中南大学湘雅二医院 | A kind of construction method of osteosarcoma xenograft mouse model |
| CN110495424B (en) * | 2019-09-09 | 2022-09-27 | 中南大学湘雅二医院 | Construction method of synovial sarcoma xenograft mouse model |
| CN110476891B (en) * | 2019-09-09 | 2022-09-23 | 中南大学湘雅二医院 | Construction method and application of synovial sarcoma xenograft mouse model |
| CN110495422B (en) * | 2019-09-23 | 2022-12-20 | 中南大学湘雅二医院 | Construction method and application of malignant schwannoma xenograft mouse model |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2013544A1 (en) * | 1989-03-31 | 1990-09-30 | Yuen Kai Fung | Retinoblastoma gene product antibodies and uses therefor |
| CN1331140A (en) * | 2000-06-26 | 2002-01-16 | 上海博德基因开发有限公司 | Polypeptide-human retinoblastome bindin (RBBP9) 25.52 and polynucleotide for coding it |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2629860A1 (en) * | 2005-11-14 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
-
2009
- 2009-10-30 CN CN 200910197959 patent/CN102053150B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2013544A1 (en) * | 1989-03-31 | 1990-09-30 | Yuen Kai Fung | Retinoblastoma gene product antibodies and uses therefor |
| CN1331140A (en) * | 2000-06-26 | 2002-01-16 | 上海博德基因开发有限公司 | Polypeptide-human retinoblastome bindin (RBBP9) 25.52 and polynucleotide for coding it |
Non-Patent Citations (4)
| Title |
|---|
| Gang EJ et al..SSEA-4 identifies mesenchymal stem cells from bone marrow.《Blood》.2006,第109卷(第4期),1743-1751. |
| SSEA-4 identifies mesenchymal stem cells from bone marrow;Gang EJ et al.;《Blood》;20061024;第109卷(第4期);1743-1751 * |
| 张伟滨.骨肉瘤生物治疗基础研究的现状.《中国肿瘤生物治疗杂志》.2008,第15卷(第2期),101-104. |
| 骨肉瘤生物治疗基础研究的现状;张伟滨;《中国肿瘤生物治疗杂志》;20080430;第15卷(第2期);101-104 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102053150A (en) | 2011-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Gelatin nanoparticle-coated silicon beads for density-selective capture and release of heterogeneous circulating tumor cells with high purity | |
| Andree et al. | Challenges in circulating tumor cell detection by the CellSearch system | |
| CN102053150B (en) | Human osteosarcoma stem cell related antigen marker and application thereof | |
| KR101604649B1 (en) | Automated enumeration and characterization of circulating melanoma cells in blood | |
| EP2655602B1 (en) | Method for identifcation and culture of multipotent mesenchymal stem cells with high proliferation potential | |
| US20190128871A1 (en) | 3d cell culture and ex vivo drug testing methods | |
| CN107748256A (en) | A kind of liquid biopsy detection method of circulating tumor cell | |
| Grzesiak et al. | Isolation and morphological characterisation of ovine adipose-derived mesenchymal stem cells in culture | |
| Lašťovička et al. | Assessment of lymphocyte proliferation for diagnostic purpose: Comparison of CFSE staining, Ki-67 expression and 3H-thymidine incorporation | |
| WO2010009121A3 (en) | Colon stem cells associated with colitis and colorectal cancer and methods of use | |
| Dekas et al. | Identification of diazotrophic microorganisms in marine sediment via fluorescence in situ hybridization coupled to nanoscale secondary ion mass spectrometry (FISH-NanoSIMS) | |
| CN105074470A (en) | Pretreatment method for sample for detecting hbs antigen, and use therefor | |
| Ju et al. | Impact of environmental pollutant cadmium on the establishment of a Cancer stem cell population in breast and hepatic Cancer | |
| Yang et al. | Deep Learning image recognition-assisted atomic force microscopy for single-cell efficient mechanics in co-culture environments | |
| CN105176922A (en) | Cell sorting method | |
| Wang et al. | Expression of microRNA miR-34a inhibits leukemia stem cells and its metastasis | |
| Bhutia et al. | Identification and characterization of stem cells in oral cancer | |
| Yao et al. | Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer | |
| Zhang et al. | Impacts of fluorescent superparamagnetic iron oxide (SPIO)-labeled materials on biological characteristics and osteogenesis of bone marrow mesenchymal stem cells (BMSCs) | |
| Longatto Filho et al. | Cytology education in the 21st century: living in the past or crossing the Rubicon? | |
| US20120315646A1 (en) | Oligothiophene derivate as molecular probes | |
| Ivanova et al. | The Content Analysis of ALDH^ sup+^ and SORE6^ sup+^ Populations of Cells in Cellular Lines of Thriple Negative Breast Cancer | |
| CN109370991A (en) | A kind of bladder cancer stem cell markers and labeling method, bladder cancer molecule parting kit and application | |
| Dobrin et al. | Cytopathology and histopathology in diagnosis of malignant cutaneous and subcutaneous mesenchymal neoplasms in dogs-a review. | |
| EP2985289A1 (en) | Depletion of mouse cells for generic isolation of human cells upon xenotransplantation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Wu Inventor after: Zhu Jiang Inventor after: Zhang Weibin Inventor before: Zhang Wu Inventor before: Zhu Jiang Inventor before: Zhang Weibin |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130717 |